The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Personalized DC Vaccine for Lung Cancer
Official Title: Neoantigen-primed DC Vaccine Therapy for Refractory Non-small Cell Lung Cancer
Study ID: NCT02956551
Brief Summary: The study is aimed to the test the efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for refractory non-small cell lung cancer.
Detailed Description: Patients with pathological confirmed non-small cell lung cancer with no standard treatment are enrolled. The patients fails in previous at least 2 lines of chemotherapy and 1 line of targeted therapy where applicable. This is a prospective exploratory trial. Patients' rebiopsy tumor tissues are subsequent to whole exosome sequencing and possible neoantigens are identified. DC is in vitro primed with synthesized peptides. Both adverse events and responses are recorded.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
China West Hospital, Chengdu, Sichuan, China
Name: Zhen-Yu Ding, Prof
Affiliation: Sichuan University
Role: PRINCIPAL_INVESTIGATOR